As of Jan 18
| -0.10 / -0.97%|
The 4 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 29.50, with a high estimate of 36.00 and a low estimate of 26.00. The median estimate represents a +187.80% increase from the last price of 10.25.
The current consensus among 4 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.